Overview
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Eligibility
Key Inclusion Criteria:
- Adults aged 18 to \<65 years
- Migraine with or without aura, per ICHD-3 criteria
- History of failure with prior preventive migraine treatments
- Not currently using migraine preventive therapy
Key Exclusion Criteria:
- Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders
- Use of certain medications
- Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities


